RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Aerpio Pharmaceuticals Stock

Aerpio Pharmaceuticals Revenue 2025

Aerpio Pharmaceuticals Revenue

-9,106.39 TT USD

Ticker

ARPO

ISIN

US00810B1052

WKN

A2PF28

In 2025, Aerpio Pharmaceuticals's sales reached -9,106.39 TT USD, a -0.4% difference from the -9,143.33 TT USD sales recorded in the previous year.

The Aerpio Pharmaceuticals Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2025e-9.11 T-
2024e-9.14 T-
2023e--
2022e--
2021e--
202015-
2019--
201820.16-
2017--
2016--
2015--

Aerpio Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aerpio Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aerpio Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aerpio Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aerpio Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aerpio Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aerpio Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aerpio Pharmaceuticals’s growth potential.

Aerpio Pharmaceuticals Revenue, EBIT and net profit per share

DateAerpio Pharmaceuticals RevenueAerpio Pharmaceuticals EBITAerpio Pharmaceuticals Net Income
2025e-9,106.39 TT undefined0 undefined-142.98 M undefined
2024e-9,143.33 TT undefined0 undefined-95.32 M undefined
2023e0 undefined0 undefined-47.66 M undefined
2022e0 undefined0 undefined0 undefined
2021e0 undefined0 undefined0 undefined
202015 M undefined-6.36 M undefined-4.32 M undefined
20190 undefined-22.58 M undefined-23.27 M undefined
201820.16 M undefined-11.18 M undefined-10.4 M undefined
20170 undefined-21.39 M undefined-21.4 M undefined
20160 undefined-16.63 M undefined-16.98 M undefined
20150 undefined-17.49 M undefined-17.07 M undefined

Aerpio Pharmaceuticals stock margins

The Aerpio Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aerpio Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aerpio Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aerpio Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Aerpio Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aerpio Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aerpio Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aerpio Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aerpio Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aerpio Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aerpio Pharmaceuticals Margin History

Aerpio Pharmaceuticals Gross marginAerpio Pharmaceuticals Profit marginAerpio Pharmaceuticals EBIT marginAerpio Pharmaceuticals Profit margin
2025e0 %0 %0 %
2024e0 %0 %0 %
2023e0 %0 %0 %
2022e0 %0 %0 %
2021e0 %0 %0 %
20200 %-42.4 %-28.8 %
20190 %0 %0 %
20180 %-55.46 %-51.59 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %

Aerpio Pharmaceuticals Aktienanalyse

What does Aerpio Pharmaceuticals do?

Aerpio Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development and commercialization of therapy options for serious diseases. The company was founded in 2011 and is headquartered in Cincinnati, Ohio. The company works with an innovative approach to offer hope for a cure through the inhibition of a specific group of enzymes. Aerpio Pharmaceuticals specializes in the research and development of therapeutics in the field of ophthalmology and cardiovascular diseases. The company is made up of an experienced team of scientists and executives who are active in the biotechnology and pharmaceutical field. The company aims to advance the clinical development of therapeutics based on the inhibition of specific enzymes. In its quest to deliver innovative results, Aerpio Pharmaceuticals is divided into two main divisions. The first division focuses on ophthalmology and seeks to develop novel therapeutics for eye diseases such as diabetic retinopathy and macular degeneration. These diseases are characterized by excessive blood vessel formation in the eye. Aerpio Pharmaceuticals aims to combat these diseases by inhibiting enzymes and researching new possibilities. The second division deals with cardiovascular diseases such as hypertension and renal insufficiency. Inhibition of enzymes can also lead to improved functions and thus have a healing effect. Aerpio Pharmaceuticals has already achieved promising results in this area and continues to strive to bring groundbreaking active substances to the market. Aerpio Pharmaceuticals has several products in the pipeline, some of which are in advanced stages of clinical studies. The company's lead product is AKB-9778, a compound aimed at inhibiting Ras-connection proteases, which is currently being investigated in phase III studies for the treatment of diabetic retinopathy and secondary retinal vein occlusion. In addition, Aerpio Pharmaceuticals has several other products in development, including AKB-4924 for the treatment of patients with pulmonary hypertension and AKB-5169, which is in phase II studies for the treatment of renal insufficiency. To sustain its business models and advance its developments, Aerpio Pharmaceuticals has a strong financial position. The company has successfully secured financing through venture capital, stock issuances, and agreements with major pharmaceutical companies. These financial resources enable Aerpio Pharmaceuticals to fund its ongoing clinical studies, develop new products, and create the infrastructure for marketing its products. In summary, Aerpio Pharmaceuticals is a biopharmaceutical company dedicated to the research, development, and commercialization of therapy options for serious diseases. With an innovative approach focused on the inhibition of specific enzymes, the specialists are dedicated to ophthalmology and cardiovascular diseases and are researching novel therapeutics with enthusiasm, marking milestones in pharmaceutical medicine and chronic patient care. Aerpio Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Aerpio Pharmaceuticals's Sales Figures

The sales figures of Aerpio Pharmaceuticals originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Aerpio Pharmaceuticals’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Aerpio Pharmaceuticals's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Aerpio Pharmaceuticals’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Aerpio Pharmaceuticals stock

How much revenue did Aerpio Pharmaceuticals generate this year?

Aerpio Pharmaceuticals has achieved a revenue of -9,106.39 TT USD this year.

How much was the turnover of the company Aerpio Pharmaceuticals compared to the previous year?

The revenue of Aerpio Pharmaceuticals has increased by -0.4% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Aerpio Pharmaceuticals?

The revenue of Aerpio Pharmaceuticals is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Aerpio Pharmaceuticals measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Aerpio Pharmaceuticals so important for investors?

The revenue of Aerpio Pharmaceuticals is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Aerpio Pharmaceuticals pay?

Over the past 12 months, Aerpio Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aerpio Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Aerpio Pharmaceuticals?

The current dividend yield of Aerpio Pharmaceuticals is .

When does Aerpio Pharmaceuticals pay dividends?

Aerpio Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aerpio Pharmaceuticals?

Aerpio Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Aerpio Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aerpio Pharmaceuticals located?

Aerpio Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aerpio Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aerpio Pharmaceuticals from 1/17/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/17/2025.

When did Aerpio Pharmaceuticals pay the last dividend?

The last dividend was paid out on 1/17/2025.

What was the dividend of Aerpio Pharmaceuticals in the year 2024?

In the year 2024, Aerpio Pharmaceuticals distributed 0 USD as dividends.

In which currency does Aerpio Pharmaceuticals pay out the dividend?

The dividends of Aerpio Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Aerpio Pharmaceuticals

Our stock analysis for Aerpio Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aerpio Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.